Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15074422 | 0.91 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17512820 | 0.89 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17512822 | 0.89 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15070679 | 0.87 | SLC28A1 (0.35) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15074434 | 0.84 | POLB (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL15074352 | 0.84 | LMNA (0.40) | P2RY6P2RY14LMNASMN1; SMN2 | |
| SCHEMBL15074353 | 0.84 | PYGM (0.38) | P2RY6P2RY2SMN1; SMN2P2RY4 | |
| SCHEMBL19993747 | 0.83 | SLC28A1 (0.36) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL17860915 | 0.83 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2526930 | 0.83 | TDP1 (0.39) | TDP1SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. (US) | 2020-01-23 | — | — | US | disclosed |
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10421771-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-10420788-B2 | — | — | 2019-09-24 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9441007-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9073960-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2015-02-19 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| WO-2014209979-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2013142525-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013096679-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464965-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20200024297-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-11021509-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TDP1 480/4885SLC28A1 22/4885SLC28A2 26/4885 |
| US-10420788-B2 | — | PNP, ADAR, NT5C2 | TDP1 167/4885SLC28A1 104/4885SLC28A2 99/4885 |
| US-20160331770-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20150051167-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20210179656-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-10421771-B2 | — | PNP, ADAR, NT5C2 | TDP1 167/4885SLC28A1 104/4885SLC28A2 99/4885 |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | TDP1 253/4885SLC28A1 38/4885SLC28A2 47/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TDP1 480/4885SLC28A1 22/4885SLC28A2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.